Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $30.00.

Several analysts have commented on KYTX shares. JPMorgan Chase & Co. dropped their price objective on Kyverna Therapeutics from $30.00 to $29.00 and set an "overweight" rating on the stock in a report on Wednesday, May 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Kyverna Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of Kyverna Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. Finally, HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd.

Kyverna Therapeutics Stock Performance

Shares of Kyverna Therapeutics stock opened at $8.25 on Tuesday. The firm has a 50-day simple moving average of $8.19 and a two-hundred day simple moving average of $8.50. The company has a debt-to-equity ratio of 0.15, a quick ratio of 9.06 and a current ratio of 9.06. Kyverna Therapeutics has a fifty-two week low of $3.60 and a fifty-two week high of $13.67. The company has a market cap of $510.18 million, a P/E ratio of -2.81 and a beta of 1.98.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.05. As a group, equities analysts predict that Kyverna Therapeutics will post -2.7 earnings per share for the current fiscal year.

Institutional Trading of Kyverna Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Allianz Asset Management GmbH purchased a new position in Kyverna Therapeutics in the 2nd quarter valued at about $98,000. California State Teachers Retirement System purchased a new stake in Kyverna Therapeutics during the 2nd quarter worth approximately $46,000. Susquehanna Fundamental Investments LLC purchased a new stake in Kyverna Therapeutics during the 2nd quarter worth approximately $404,000. Wellington Management Group LLP acquired a new position in shares of Kyverna Therapeutics during the second quarter valued at approximately $1,046,000. Finally, Bank of America Corp DE acquired a new position in shares of Kyverna Therapeutics during the second quarter valued at approximately $2,365,000. Hedge funds and other institutional investors own 18.08% of the company's stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.